Condition

Primary Peritoneal Cancer clinical trials and research

• 22Clinical trials
• 1New in 30 days
• 32Countries

Newest Primary Peritoneal Cancer clinical trials

All recruiting trials (22)

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer (REGYNERA-tion) Registry

  This registry tests how reirradiation and total ablative strategies are used in real-world care for adults with recurrent gynecologic cancers and tracks outcomes to see what happens after these treatments.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość, Lublin Voivodeship · NCT07667192

• Romiplostim N01 plus ATRA for persistent chemotherapy-induced low platelets after remission from gynecologic, breast, or lung cancer

  This trial tests whether adding ATRA to Romiplostim N01 helps people keep a safe platelet count after finishing chemotherapy for certain cancers.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07586826

• PARP inhibitor with or without an angiogenesis inhibitor for HRD advanced ovarian, fallopian-tube, or primary peritoneal cancer

  This trial will test whether adding the angiogenesis drug bevacizumab to a PARP inhibitor helps people with homologous recombination deficient (HRD) stage III–IV ovarian, fallopian-tube, or primary peritoneal cancer.

  Recruiting Phase 2/3 N.N. Alexandrov National Cancer Centre · Minsk, Lesnoy · NCT07472140

• Aitua plus Nab-Paclitaxel and Carboplatin before surgery for advanced high-grade serous ovarian cancer

  This trial tests whether adding the PD-1/CTLA-4 bispecific antibody Aitua to standard neoadjuvant chemotherapy helps achieve complete tumor removal before interval debulking surgery in newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer patients who are not expected to be debulked to no visib

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07432594

• Giving TORL-1-23 with chemotherapy before initial surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer

  This study will test whether adding TORL-1-23 to standard paclitaxel and carboplatin before initial surgery helps women with advanced (FIGO III/IV) ovarian, fallopian tube, or primary peritoneal cancer whose tumors are CLDN6-positive.

  Recruiting at 7 sites Phase 1/2 TORL Biotherapeutics, LLC · Fullerton, California and 6 other locations · NCT07322094

• BL-B01D1 versus doctor‑chosen chemotherapy for platinum‑resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

  This tests whether BL-B01D1 works better than the doctor’s choice of chemotherapy for adults with platinum‑resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06994195

• Combining carboplatin with mirvetuximab soravtansine before surgery for FRα-positive advanced serous ovarian, fallopian tube, or primary peritoneal cancer

  This will test whether giving mirvetuximab soravtansine with carboplatin before surgery helps people with newly diagnosed FRα-positive advanced-stage serous ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 71 sites Phase 2 AbbVie · Birmingham, Alabama and 72 other locations · NCT06890338

• Cirtuvivint plus Olaparib for BRCA/HRD-positive, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer

  We will test whether adding cirtuvivint to daily olaparib is safe and tolerable for women with BRCA- or HRD-positive, platinum-resistant high-grade ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 2 sites Phase 1 University of Colorado, Denver · Aurora, Colorado and 1 other locations · NCT06856499

• Evaluating a new treatment for recurrent ovarian cancer

  This study is testing a new treatment for women with recurrent ovarian cancer to see if it helps them live longer and feel better compared to standard care.

  Recruiting at 201 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 201 other locations · NCT06824467

• Evaluating SIM0505 for advanced solid tumors

  This study is testing a new treatment called SIM0505 to see if it is safe and effective for adults with advanced solid tumors that haven't responded to other therapies.

  Recruiting at 6 sites Phase 1 NextCure, Inc. · Orlando, Florida and 16 other locations · NCT06792552

• Ubamatamab alone and with other cancer drugs for platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer

  This trial will test whether ubamatamab by itself or combined with bevacizumab, cemiplimab, fianlimab, or pegylated liposomal doxorubicin helps adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 56 sites Phase 2 Regeneron Pharmaceuticals · Birmingham, Alabama and 55 other locations · NCT06787612

• Reducing fatigue in adults with ovarian cancer on PARP inhibitors

  This study is testing a tele-health program called REVITALIZE to see if it can help reduce fatigue and improve daily life for adults with ovarian cancer who are taking PARP inhibitors.

  Recruiting at 6 sites Dana-Farber Cancer Institute · Aurora, Colorado and 5 other locations · NCT06710548

• Mirvetuximab soravtansine for platinum-resistant high-grade ovarian, fallopian tube, and primary peritoneal cancer with high folate receptor-alpha

  This trial tests whether intravenous mirvetuximab soravtansine helps people with platinum-resistant high-grade ovarian, fallopian tube, or primary peritoneal cancer whose tumors have high folate receptor-alpha.

  Recruiting at 52 sites Phase 2 AbbVie · Sarasota, Florida and 51 other locations · NCT06682988

• HS-20089 treatment for ovarian and endometrial cancer

  This study is testing a new treatment called HS-20089 to see if it can help people with recurrent or advanced ovarian and endometrial cancer feel better.

  Recruiting at 26 sites Phase 2 Hansoh BioMedical R&D Company · Hefei, Anfei and 27 other locations · NCT06014190

• Treatment of advanced solid tumors with AVZO-021

  This study is testing a new oral medication called AVZO-021 to see if it can safely help people with advanced solid tumors, especially certain types of breast cancer and other cancers with specific genetic changes.

  Recruiting at 13 sites Phase 1/2 Avenzo Therapeutics, Inc. · New Haven, Connecticut and 12 other locations · NCT05867251

• Adding IMNN-001 to chemotherapy for advanced ovarian cancer

  This study is testing if adding a new treatment called IMNN-001 to standard chemotherapy can help people with advanced ovarian cancer do better than with chemotherapy alone.

  Recruiting at 2 sites Phase 1/2 Imunon · Baltimore, Maryland and 3 other locations · NCT05739981

• Characterizing ovarian cancer patients based on genetic factors

  This study looks at how genetic factors affect the treatment responses of women with ovarian cancer to see if they respond differently to standard chemotherapy over time.

  Recruiting Nordic Society of Gynaecological Oncology - Clinical Trials Unit · København Ø, Region Sjælland · NCT05574673

• Evaluating Olvi-Vec with chemotherapy for advanced ovarian cancer

  This study is testing if a new virus-based treatment called Olvi-Vec, combined with chemotherapy, can help women with tough-to-treat advanced ovarian cancer live longer and feel better.

  Recruiting at 33 sites Phase 3 Genelux Corporation · Mobile, Alabama and 32 other locations · NCT05281471

• Treatment of advanced or metastatic solid tumors with ART0380

  This study is testing a new drug called ART0380 to see if it can safely help people with advanced solid tumors that have specific DNA repair issues, either on its own or with other chemotherapy drugs.

  Recruiting at 62 sites Phase 1/2 Artios Pharma Ltd · Birmingham, Alabama and 87 other locations · NCT04657068

• Carboplatin and Mirvetuximab for Advanced Ovarian Cancer Treatment

  This study is testing if a combination of carboplatin and mirvetuximab can help women with advanced ovarian cancer do better after their initial chemotherapy before surgery.

  Recruiting at 9 sites Phase 2 University of Alabama at Birmingham · Birmingham, Alabama and 8 other locations · NCT04606914

• Investigating the safety and effectiveness of REGN5668 with other drugs for advanced ovarian and uterine cancers

  This study is testing if a new drug called REGN5668, used with other medications, can safely help people with advanced ovarian or uterine cancers.

  Recruiting at 27 sites Phase 1/2 Regeneron Pharmaceuticals · Duarte, California and 27 other locations · NCT04590326

Related topics

Quick answers

How many Primary Peritoneal Cancer clinical trials are recruiting right now?

22, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 32 countries. The most sites are in United States (14 trials), China (5 trials), France (4 trials), Poland (4 trials), Spain (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 7, Phase 1/2: 5, Phase 3: 3, Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →